

chain nodes :

7 8 9 12 19 20

ring nodes :

1 2 3 4 5 6 10 13 14 15 16 21

chain bonds :

6-7 7-8 8-9 9-10 9-12 19-20 19-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-13 10-16 13-14 14-15 15-16

exact/norm bonds :

7-8 8-9 9-10 9-12 10-13 10-16 13-14 14-15 15-16 19-20 19-21

exact bonds :

6-7

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,N

G2:O,S

G3:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:Atom 12:CLASS13:Atom 14:Atom

15:Atom 16:Atom 19:CLASS20:CLASS21:Atom 22:Atom

10/541,460

=> d his

(FILE 'HOME' ENTERED AT 11:12:32 ON 20 MAR 2007)

FILE 'REGISTRY' ENTERED AT 11:12:43 ON 20 MAR 2007

L1 STRUCTURE UPLOADED
L2 10 S L1
L3 326 S L1 SSS FUL
L4 325 S L3 AND CAPLUS/LC
L5 1 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 11:13:20 ON 20 MAR 2007

L6 6 S L3


FILE 'REGISTRY' ENTERED AT 11:13:47 ON 20 MAR 2007

FILE 'CAPLUS' ENTERED AT 11:13:47 ON 20 MAR 2007

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,N

G2 O,S

G3 C,N

Structure attributes must be viewed using STN Express query preparation.


=> d l5

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y


10/541,460

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 735260-81-8 REGISTRY
ED Entered STN: 30 Aug 2004
CN 1-Piperazinecarboxamide, N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)
MF C22 H28 N4 O2 S
CI COM
SR CA

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/541,460

=> d ibib abs hitstr total 16

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:195980 CAPLUS

DOCUMENT NUMBER: 144:274313

TITLE: Preparation of tetraaza-benzo[f]azulenes as vasopressin Vla antagonists

INVENTOR(S): Andrzej, Roman Batt; Baxter, Andrew John; Heeney, Celine; Stockley, Martin Lee; Bryan Roe, Michael; Hudson, Peter; Handy, Rachel

PATENT ASSIGNEE(S): Ferring B.V., Neth.

SOURCE: PCT Int. Appl., 463 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021213	A2	20060302	WO 2005-DK540	20050824
WO 2006021213	A3	20060817		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1632494	A1	20060308	EP 2004-104062	20040824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
AU 2005276790	A1	20060302	AU 2005-276790	20050824
CA 2567776	A1	20060302	CA 2005-2567776	20050824
PRIORITY APPLN. INFO.:			EP 2004-104062	A 20040824
			US 2004-603557P	P 20040824
			WO 2005-DK540	W 20050824
OTHER SOURCE(S):			MARPAT 144:274313	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [G = NR5R6, II-V; A1 = CH₂, CH(OH), NH, N(alkyl), O and S; A2 = CH₂, CH(OH), C(O), NH; A3, A12 = S, NH, N(alkyl), etc.; A4, A13 = CR₉, N; A5, A14 = CR₁₀, N; A6 = CH₂, NH, N(alkyl), O; A7, A11 = C, N; A8, A9 = CH, N, NH, S, etc.; A10 = CH:CH, CH, N, NH, etc.; the ring constituted by A7-A11 is aromatic; R1-R3 = H, alkyl, O(alkyl), NO₂, F, Cl, Br; R4 = H, alkyl, aryl, heteroaryl, etc.; R5, R6 = alkyl, aryl, (CH₂)f-aryl, (CH₂)f-heteroaryl; R9, R10 = H, alkyl, alkoxy, etc.; W = O, NH; X = (CH₂)_m, C(O), SO_j; Y = O, S, NH, N(alkyl); a, f, j = 1-2; m = 0-2; with provisos] which are vasopressin Vla receptor antagonists, were prepared and formulated. E.g., a multi-step synthesis of 4-(3,3-

dimethylbutyl)piperazine-1-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluorobenzylamide, starting from 4-(tert-butoxycarbonylamino-methyl)-3-fluorobenzoic acid and 3,6-dimethyl-3,4,9,10-tetrahydro-2,3,4,9-tetraazabenzofazulene (prepns. of the reactants was provided), was given. Compds. I were assayed to determine their ability to inhibit the cellular consequences of AVP stimulation on intact cells. In the assay, compds. I cause significant inhibition of cellular activation at concns. of 30 μ M or less. Preferred compds. I cause significant inhibition at concns. of 300 nM. Pharmaceutical compns. of the compds. I are useful as treatment of dysmenorrhea.

IT 877843-67-9P 877843-69-1P 877843-71-5P

877843-73-7P 877843-75-9P 877843-77-1P

877843-79-3P 877843-81-7P 877843-82-8P

877843-86-2P 877843-89-5P 877843-90-8P

877843-91-9P 877843-92-0P 877843-93-1P

877843-94-2P 877843-95-3P 877843-96-4P

877843-97-5P 877843-98-6P 877843-99-7P

877844-00-3P 877844-01-4P 877844-02-5P

877844-03-6P 877844-04-7P 877844-05-8P

877844-06-9P 877844-07-0P 877844-08-1P

877844-09-2P 877844-10-5P 877844-11-6P

877844-12-7P 877844-17-2P 877844-18-3P

877844-19-4P 877844-20-7P 877844-21-8P

877844-22-9P 877844-23-0P 877844-24-1P

877844-25-2P 877844-26-3P 877844-27-4P

877844-28-5P 877844-29-6P 877844-30-9P



877844-31-0P 877859-73-9P 877859-75-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetraaza-benzo[f]azulenes as vasopressin V1a antagonists)

RN 877843-67-9 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-fluorophenyl)methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)




RN 877843-69-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 877843-73-7 CAPLUS
 CN 1-Piperazinecarboxamide, 4-cyclopropyl-N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 877843-75-9 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 877843-77-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopentylmethyl)-N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877843-79-3 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)




RN 877843-81-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877843-82-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877843-86-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-fluorophenyl)methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877843-89-5 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-fluorophenyl)methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 877843-90-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3,3-dimethylbutyl)-N-[[2-fluoro-4-[(8-fluoro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877843-91-9 CAPLUS


CN 1-Piperazinecarboxamide, N-[[[2-chloro-4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)




RN 877843-92-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877843-93-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)




RN 877843-94-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877843-95-3 CAPLUS


CN 1-Piperazineacetic acid, 4-[[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 877843-96-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[4-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-2-methylphenyl]methyl]piperazine-4-carboxylic acid (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877843-97-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(cyclopentylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877843-98-6 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 877843-99-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-cyclopropyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-00-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3-methylbutyl)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 877844-01-4 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)





RN 877844-02-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-propyl- (9CI) (CA INDEX NAME)





RN 877844-03-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)





RN 877844-04-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)





RN 877844-05-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-propyl-(9CI) (CA INDEX NAME)





RN 877844-06-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[[4-(4,10-dihydro-1,7-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)



RN 877844-07-0 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,9-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-fluorophenyl)methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)




RN 877844-08-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-09-2 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(3,4-dihydro-8-methyl-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-10-5 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(2,3-dihydro-7-methyl-4H-1,4-benzoxazin-4-yl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-11-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(7-chloro-2,3-dihydro-4H-1,4-benzoxazin-4-yl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 877844-12-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(3,4-dihydro-8-methyl-1(2H)-quinolinyl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI)
(CA INDEX NAME)




RN 877844-17-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,5-dihydro-2,9-dimethyl-6H-thiazolo[5,4-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-18-3 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,5-dihydro-2-methyl-6H-thiazolo[5,4-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-19-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,5-dihydro-2-methyl-6H-thiazolo[5,4-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-20-7 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-21-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 877844-22-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)



RN 877844-23-0 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-methylphenyl)methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 877844-25-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877844-26-3 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-fluorophenyl)methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)




RN 877844-27-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-fluorophenyl)methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-28-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[3-chloro-4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-29-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[3-chloro-4-[(8-chloro-4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-30-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[3-chloro-4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877844-31-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[3-chloro-4-[(4,10-dihydro-1,8-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877859-73-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877859-75-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,5-dihydro-2-methyl-6H-oxazolo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:167754 CAPLUS

DOCUMENT NUMBER: 144:254156

TITLE: Preparation of heterocyclic condensed compounds useful
as antidiuretic agents

INVENTOR(S): Pitt, Gary Robert William

PATENT ASSIGNEE(S): Ferring B.V., Neth.

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018443	A1	20060223	WO 2005-EP54081	20050818
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1627876	A1	20060222	EP 2004-104006	20040820
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CA 2567782	A1	20060223	CA 2005-2567782	20050818
PRIORITY APPLN. INFO.:			EP 2004-104006	A 20040820
			US 2004-602890P	P 20040820
			WO 2005-EP54081	W 20050818

OTHER SOURCE(S): MARPAT 144:254156

GI



I



II

AB The title compds. I [W = N, CR₄; X = O, S, C(O), etc.; G₁ = bicyclic or tricyclic fused azepine; R₁, R₂ = H, halo, alkyl, etc.; R₃ = H, alkyl; R₄-R₇ = H, halo, alkyl, etc.; a = 1-3] which are vasopressin V₂ receptor agonists, were prepared and formulated. E.g., a multi-step synthesis of II, starting from 1,2-difluoro-3-nitrobenzene and β-alanine Me ester hydrochloride, was given. V₂ receptor agonist activity was determined for all compds. and all the compds. I cause significant cellular activation at 30 μM or less. Pharmaceutical compns. of the compds. I are useful as antidiuretic agents.


IT 877228-68-7P 877228-69-8P 877228-74-5P
877228-75-6P 877228-76-7P 877228-77-8P
877228-80-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heterocyclic condensed compds. useful as antidiuretic agents)

RN 877228-68-7 CAPLUS


CN 1H-1,5-Benzodiazepine-1-acetic acid, 6-fluoro-2,3,4,5-tetrahydro-5-[[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]amino]carbonyl]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10/541,460


RN 877228-69-8 CAPLUS

CN 1H-1,5-Benzodiazepine-1-acetic acid, 6-fluoro-2,3,4,5-tetrahydro-5-[[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl)methyl]amino]carbonyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 877228-74-5 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl)methyl]amino]carbonyl]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 2-A




RN 877228-75-6 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl)methyl]amino]car
 bonyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877228-76-7 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(2-hydroxyethyl)-N-
 [[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877228-77-8 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo-4-
 (2-oxoethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877228-80-3 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-(cyanomethyl)-8-fluoro-3,4-dihydro-N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)



IT 877228-70-1P 877228-78-9P 877228-79-0P
877228-81-4P 877228-82-5P 877228-83-6P
877228-84-7P 877228-85-8P 877228-87-0P
877229-06-6P 877229-07-7P 877229-08-8P
877229-09-9P 877229-14-6P 877229-15-7P
877229-16-8P 877229-17-9P 877229-18-0P
877229-19-1P 877229-22-6P 877229-23-7P
877229-24-8P 877229-25-9P 877229-26-0P
877229-27-1P 877229-28-2P 877229-29-3P
877229-30-6P 877229-31-7P 877229-32-8P
877229-33-9P 877229-34-0P 877229-35-1P
877229-36-2P 877229-37-3P 877229-38-4P
877229-39-5P 877229-40-8P 877229-41-9P
877229-42-0P 877229-43-1P 877229-44-2P
877229-45-3P 877229-46-4P 877229-47-5P
877229-48-6P 877229-49-7P 877229-50-0P
877229-51-1P 877229-52-2P 877229-53-3P


877229-54-4P 877229-55-5P 877229-56-6P
 877229-57-7P 877229-58-8P 877229-59-9P
 877229-60-2P 877229-61-3P 877229-62-4P
 877229-63-5P 877229-64-6P 877229-65-7P
 877229-66-8P 877229-67-9P 877229-68-0P
 877229-69-1P 877229-70-4P 877229-71-5P
 877229-72-6P 877229-73-7P 877229-74-8P
 877229-75-9P 877229-76-0P 877229-77-1P
 877229-78-2P 877229-79-3P 877229-80-6P
 877229-81-7P 877229-82-8P 877229-83-9P
 877229-84-0P 877229-85-1P 877229-86-2P
 877229-87-3P 877229-88-4P 877229-89-5P
 877229-90-8P 877229-91-9P 877229-92-0P
 877229-93-1P 877229-94-2P 877229-95-3P
 877229-96-4P 877229-97-5P 877229-98-6P
 877230-00-7P 877230-02-9P 877230-03-0P
 877230-04-1P 877230-05-2P 877230-06-3P
 877230-07-4P 877230-08-5P 877230-09-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic condensed compds. useful as antidiuretic agents)

RN 877228-70-1 CAPLUS


CN 1H-1,5-Benzodiazepine-1-carboxamide, 9-fluoro-2,3,4,5-tetrahydro-5-(2-hydroxyethyl)-N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 877228-78-9 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-[2-(methylamino)ethyl]-N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877228-79-0 CAPLUS
 CN 1(2H)-Quinoxalineacetic acid, 5-chloro-3,4-dihydro-4-[[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]amino]car
 bonyl]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877228-81-4 CAPLUS


CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl)methyl]-3-oxo-4-
 (1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 877228-82-5 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-(3-aminopropyl)-8-fluoro-3,4-dihydro-N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877228-83-6 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(2-methoxyethyl)-N-
 [[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
 ylcarbonyl)phenyl)methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877228-84-7 CAPLUS


CN 1(2H)-Quinoxalineacetic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 877228-85-8 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-methyl-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 877228-87-0 CAPLUS


CN 1H-1,4-Benzodiazepine-1-carboxamide, 9-fluoro-2,3,4,5-tetrahydro-N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-5-oxo- (9CI) (CA INDEX NAME)




RN 877229-06-6 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-chloro-3,4-dihydro-4-methyl-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-07-7 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-methyl-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-08-8 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 7,8-difluoro-3,4-dihydro-4-methyl-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-09-9 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-ethyl-8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-14-6 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-15-7 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(methoxyacetyl)-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-16-8 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(3-methoxy-1-oxopropyl)-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-yl]carbonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-17-9 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(2-hydroxyethyl)-N-
 [[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
 ylcarbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-18-0 CAPLUS
 CN 1(2H)-Quinoxalineacetic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 877229-19-1 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 877229-22-6 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-(cyclopropylmethyl)-8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-23-7 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-chloro-3,4-dihydro-4-(2-hydroxyethyl)-N-
 [[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-24-8 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 5-chloro-3,4-dihydro-4-[[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl)methyl]amino]car
 bonyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-25-9 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 7,8-difluoro-3,4-dihydro-4-(2-hydroxyethyl)-
 N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-26-0 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 5,6-difluoro-3,4-dihydro-4-[[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]amino]car
 bonyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-27-1 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 5,6-difluoro-3,4-dihydro-4-[[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]amino]car
 bonyl]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 877229-28-2 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo-
 (9CI) (CA INDEX NAME)



RN 877229-29-3 CAPLUS


CN 1H-1,5-Benzodiazepine-1-carboxamide, 9-fluoro-2,3,4,5-tetrahydro-N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 877229-30-6 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]amino]carbonyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-31-7 CAPLUS

CN 1(2H)-Quinoxalinepropanoic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]amino]car
 bonyl]-2-oxo-, cyclopropylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-32-8 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(2-methoxyethyl)-N-
 [[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-33-9 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-(2-ethoxyethyl)-8-fluoro-3,4-dihydro-N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-34-0 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-[2-(acetyloxy)ethyl]-8-fluoro-3,4-dihydro-
 N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-35-1 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-(2-aminoethyl)-8-fluoro-3,4-dihydro-N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-36-2 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-[2-(diethylamino)ethyl]-8-fluoro-3,4-dihydro-N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-37-3 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 4-[3-(acetyloxy)propyl]-8-fluoro-3,4-dihydro-
 N-[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-38-4 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(2-methylpropyl)-N-
 [[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbamoyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-39-5 CAPLUS

CN 1(2H)-Quinoxalineacetamide, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl)methyl]amino]car-
 bonyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-40-8 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-chloro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-3-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-41-9 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 7,8-difluoro-3,4-dihydro-4-(2-hydroxyethyl)-
 N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
 ylcarbonyl)phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 877229-42-0 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 5,6-difluoro-3,4-dihydro-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 877229-43-1 CAPLUS
 CN 1(2H)-Quinoxalineacetic acid, 5,6-difluoro-3,4-dihydro-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-44-2 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(3-hydroxypropyl)-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 877229-45-3 CAPLUS
 CN 1(2H)-Quinoxalinepropanoic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 877229-46-4 CAPLUS
 CN 1(2H)-Quinoxalinepropanoic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-47-5 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 7,8-difluoro-3,4-dihydro-4-methyl-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-48-6 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-3-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-49-7 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 7,8-difluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-3-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-50-0 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 6,7,8-trifluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 877229-51-1 CAPLUS
 CN 1(2H)-Quinoxalineacetamide, 5-fluoro-3,4-dihydro-N,N-dimethyl-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 877229-52-2 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 4-[3-(acetyloxy)propyl]-8-fluoro-3,4-dihydro-
 N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
 ylcarbonyl)phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-53-3 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-(2-ethoxyethyl)-8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-54-4 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(methoxymethyl)-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-55-5 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-(2-hydroxyethyl)-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-56-6 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-57-7 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-58-8 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 4-(cyclopropylmethyl)-8-fluoro-3,4-dihydro-N-
 [[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
 ylcarbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-59-9 CAPLUS

CN 1(2H)-Quinoxalinepropanoic acid, 5-fluoro-3,4-dihydro-4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]amino]carbonyl]-2-oxo-, cyclopropylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 877229-60-2 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-3-oxo-4-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 877229-61-3 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 4-ethyl-8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 877229-62-4 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-(2-aminoethyl)-8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)




RN 877229-63-5 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 4-(cyanomethyl)-8-fluoro-3,4-dihydro-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-64-6 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-methyl-3-oxo-N-[[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-65-7 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-3-oxo-N-[[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-66-8 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-methyl-N-[[2-methyl-4-
 [(5-oxo-5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
 yl)carbonyl]phenyl)methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-67-9 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-methyl-N-[[2-methyl-4-(4H-pyrazolo[5,1-c][1,4]benzodiazepin-5(10H)-ylcarbonyl)phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877229-68-0 CAPLUS


CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-methyl-N-[[2-methyl-4-(thieno[3,4-b][1,5]benzoxazepin-9(10H)-yl)carbonyl]phenyl]methyl]-3-oxo-(9CI) (CA INDEX NAME)




RN 877229-69-1 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-4-methyl-N-[[2-methyl-4-
[(2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-1-yl)carbonyl]phenyl]methyl]-3-
oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-70-4 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(5-ethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-1-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-4-methyl-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-71-5 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-
[[2,3,4,5-tetrahydro-5-(2-hydroxyethyl)-1H-1,5-benzodiazepin-1-
yl]carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-72-6 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(2,3-dihydro-4,1-benzoxazepin-1(5H)-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-4-methyl-3-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 877229-73-7 CAPLUS


CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-4-methyl-3-oxo-(9CI) (CA INDEX NAME)




RN 877229-74-8 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-4-(3-hydroxypropyl)-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-75-9 CAPLUS

CN 1(2H)-Quinoxalinepropanoic acid, 4-[[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-5-fluoro-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-76-0 CAPLUS

CN 1(2H)-Quinoxalinepropanoic acid, 4-[[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-5-fluoro-3,4-dihydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-77-1 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-78-2 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl)methyl]-8-fluoro-3,4-dihydro-4-(2-methoxyethyl)-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-79-3 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl)methyl]-8-fluoro-3,4-dihydro-4-(2-hydroxyethyl)-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-80-6 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 4-[[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-5-fluoro-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-81-7 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 4-[[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-5-fluoro-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-82-8 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 4-(2-aminoethyl)-N-[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl)methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-83-9 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo-4-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-84-0 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 4-(cyanomethyl)-N-[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl)methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-85-1 CAPLUS

CN 1(2H)-Quinoxalineacetamide, 4-[[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-5-fluoro-3,4-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-86-2 CAPLUS

CN 1(2H)-Quinoxalineacetamide, 4-[[[4-[(3,4-dihydro-1,5-benzoxazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-5-fluoro-3,4-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-87-3 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(5,5-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-88-4 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 4-[[[4-[(5,5-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-5-fluoro-3,4-dihydro-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-89-5 CAPLUS

CN 1(2H)-Quinoxalineacetic acid, 4-[[[4-[(5,5-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-5-fluoro-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-90-8 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(5,5-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-4-(2-hydroxyethyl)-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-91-9 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-
 [(2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-
 yl)carbonyl]phenyl]methyl]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-92-0 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(3,4-dihydro-1,5-benzothiazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CAPLUS INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 877229-93-1 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(3,4-dihydro-1,1-dioxido-1,5-benzothiazepin-5(2H)-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)




RN 877229-94-2 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(4,5-dihydro-2-methylpyrazolo[4,3-d][1]benzazepin-6(2H)-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-95-3 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-
[[2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl) carbonyl]phenyl]methyl]-3-
oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-96-4 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-
 [(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]-3-
 oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877229-97-5 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[2-methyl-4-(pyrido[2,3-b][1,5]benzoxazepin-6(5H)-ylcarbonyl)phenyl]methyl]-3-oxo-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 877229-98-6 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(6,7-dihydro-5H-dibenz[b,d]azepin-5-yl)carbonyl]-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)




RN 877230-00-7 CAPLUS


10/541,460

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(4,5-dihydro-6H-thieno[3,2-d][1]benzazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877230-02-9 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[2-chloro-4-(thieno[3,4-b][1,5]benzoxazepin-9(10H)-ylcarbonyl)phenyl)methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877230-03-0 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[2-chloro-4-[(2,3,4,5-tetrahydro-5-methyl-1H-1,5-benzodiazepin-1-yl)carbonyl]phenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877230-04-1 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, N-[[2-ethyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877230-05-2 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, 8-fluoro-3,4-dihydro-N-[[3-methyl-4-
 [(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-3-oxo-
 (9CI) (CA INDEX NAME).

PAGE 1-A




PAGE 2-A




RN 877230-06-3 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[2-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877230-07-4 CAPLUS
 CN 1(2H)-Quinoxalinecarboxamide, N-[[2,5-dimethyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl) carbonyl]phenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877230-08-5 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl) carbonyl]-2-ethylphenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 877230-09-6 CAPLUS

CN 1(2H)-Quinoxalinecarboxamide, N-[[2-chloro-4-[(5,6,7,8-tetrahydro-4H-thieno[2,3-b][1,4]diazepin-4-yl)carbonyl]phenyl]methyl]-8-fluoro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




- IT 877230-92-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heterocyclic condensed compds. useful as antidiuretic agents)
- RN 877230-92-7 CAPLUS
- CN Carbamic acid, [3-[5-fluoro-3,4-dihydro-4-[[[2-methyl-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl)methyl]amino]carbonyl]-2-oxo-1(2H)-quinoxalinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:209542 CAPLUS

DOCUMENT NUMBER: 142:280234

TITLE: Synthesis of piperazines as oxytocin agonists

INVENTOR(S): Hudson, Peter; Pitt, Gary Robert William; Batt, Andrej Roman; Roe, Michael Bryan

PATENT ASSIGNEE(S): Ferring B.V., Neth.

SOURCE: Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1512687	A1	20050309	EP 2003-20177	20030905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CA 2535744	A1	20050317	CA 2004-2535744	20040902
WO 2005023812	A2	20050317	WO 2004-EP52006	20040902
WO 2005023812	A3	20050506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1660501	A2	20060531	EP 2004-766681	20040902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007504263	T	20070301	JP 2006-525816	20040902
PRIORITY APPLN. INFO.:			EP 2003-20177	A 20030905
			WO 2004-EP52006	W 20040902
OTHER SOURCE(S):		CASREACT 142:280234; MARPAT 142:280234		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Novel benzo[f]azulene benzylamides I [R1, R2, R3 = independently H, alkyl, F, Cl, R4 = 3,5-(HO)2C6H3CH2, 3-Me2NCOC6H4CH2, 3-Me2NC(S)C6H4CH2] were prepared as human OT agonists. Thus, reacting 4-cyano-3-methylbenzoic acid with 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraazabenzof[f]azulene gave the corresponding carbonyl benzonitrile which was reacted with CoCl/MeOH followed by NaBH4 to give the methanone II. II was then added to 5-[(piperazin-1-yl)methyl]benzene-1,3-diol to give I [R1 = Me, R2 = R3 = H, R4 = 3,5-(HO)2C6H3CH2] in 28% yield. The compds. are intended to be used as human OT agonists for treating a variety of conditions for which inadequate oxytocin-like activity is implicated in the pathophysiol.

IT 847375-16-0P 847375-19-3P 847375-20-6P

10/541,460

847375-21-7P 847375-22-8P 847375-23-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperazinecarboxylic acid (benzo[f]azulenecarbonyl)benzylamides as human oxytocin agonists)


RN 847375-16-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[(3,5-dihydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847375-19-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-fluorophenyl)methyl]-4-[(3,5-dihydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 847375-20-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2,6-dimethylphenyl)methyl]-4-[(3,5-dihydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 847375-21-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[[3-chloro-4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 847375-22-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[[3-[(dimethylamino)carbonyl]phenyl)methyl]- (9CI) (CA INDEX NAME)





2



RN 847375-23-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[3-[(dimethylamino)thioxomethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:700283 CAPLUS

DOCUMENT NUMBER: 141:207237

TITLE: Preparation of substituted pyrazolo-fused
benzodiazepine analogs as oxytocin agonists and
vasopressin antagonistsINVENTOR(S): Hudson, Peter; Batt, Andrzej Roman; Laurent, Celine
Marguerite Simone; Baxter, Andrew John; Roe, Michael
Bryan; Robson, Peter Andrew

PATENT ASSIGNEE(S): Ferring B.V., Neth.

SOURCE: Eur. Pat. Appl., 71 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1449844	A1	20040825	EP 2003-3394	20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004212140	A1	20040826	AU 2004-212140	20040212
CA 2513220	A1	20040826	CA 2004-2513220	20040212
WO 2004072083	A1	20040826	WO 2004-EP1304	20040212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1592693	A1	20051109	EP 2004-710384	20040212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1751050	A	20060322	CN 2004-80004232	20040212
JP 2006517530	T	20060727	JP 2006-500029	20040212
NO 2005004225	A	20051114	NO 2005-4225	20050912
US 2006166971	A1	20060727	US 2006-541460	20060306
PRIORITY APPLN. INFO.:			EP 2003-3394	A 20030214
			WO 2004-EP1304	W 20040212
OTHER SOURCE(S):			MARPAT 141:207237	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [G1 = amino, fused polycyclic group; R1-3 = H, alkyl, alkoxy, F, Cl, Br; R4 = H, alk(en/yn)yl, Ph, etc.; X1 = O, NH; n = 1-2; m = 1-3] are prepared For instance, 4-cyano-3-methylbenzoic acid (preparation given) was coupled to 1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine (preparation given; PhMe, SOCl₂; CH₂Cl₂, Et₃N) and the product reduced to the corresponding aminomethyl derivative (MeOH, CoCl₂, NaBH₄), coupled to tert-Bu piperazine-1-carboxylate (DMF, i-Pr₂NEt, CDI), deprotected (dioxane, 4N HCl) and reductively alkylated with

cyclopropanecarboxaldehyde (THF, Et₃N, NaCNBH₃) to give II. I are selective and potent oxytocin agonists and/or vasopressin V_{1a} antagonists useful in the treatment of, inter alia, primary dysmenorrhea.

IT 500011-99-4P 500012-00-0P 500012-01-1P
 500012-02-2P 500012-03-3P 500012-04-4P
 500012-05-5P 500012-06-6P 500012-07-7P
 500012-08-8P 500012-09-9P 500012-10-2P
 500012-11-3P 500012-12-4P 500012-13-5P
 500012-14-6P 500012-15-7P 500012-16-8P
 500012-17-9P 500012-19-1P 500012-20-4P
 500012-21-5P 500012-22-6P 500012-23-7P
 500012-24-8P 500012-25-9P 500012-26-0P
 500012-27-1P 500012-28-2P 500012-29-3P
 500012-30-6P 500012-31-7P 500012-32-8P
 500012-33-9P 500012-34-0P 500012-35-1P
 500012-36-2P 500012-37-3P 500012-38-4P
 500012-39-5P 500012-40-8P 500012-41-9P
 500012-42-0P 500012-43-1P 500012-44-2P
 500012-45-3P 500012-46-4P 500012-47-5P
 500012-48-6P 500012-49-7P 500012-50-0P
 500012-51-1P 500012-52-2P 500012-53-3P
 500012-54-4P 500012-55-5P 500012-56-6P
 500012-57-7P 500012-58-8P 500012-59-9P
 500012-60-2P 500012-61-3P 500012-62-4P
 500012-63-5P 500012-64-6P 500012-65-7P
 500012-66-8P 500012-67-9P 500012-68-0P
 500012-69-1P 500012-70-4P 500012-71-5P
 500012-72-6P 500012-73-7P 500012-74-8P
 500012-75-9P 500012-76-0P 500012-77-1P
 500012-78-2P 500012-79-3P 500012-80-6P
 500012-81-7P 500012-82-8P 500012-83-9P
 500012-84-0P 500012-85-1P 500012-86-2P
 500012-87-3P 500012-88-4P 500012-89-5P
 500012-90-8P 500012-91-9P 500012-92-0P
 500012-93-1P 500012-94-2P 500012-95-3P
 500012-96-4P 500012-97-5P 500012-98-6P
 500012-99-7P 500013-00-3P 500013-01-4P
 500013-02-5P 500013-03-6P 500013-04-7P
 500013-05-8P 500013-06-9P 500013-07-0P
 500013-09-2P 500013-10-5P 500013-11-6P
 500013-12-7P 500013-13-8P 500013-14-9P
 500013-15-0P 500013-16-1P 500013-17-2P
 500013-18-3P 500013-19-4P 744200-14-4P
 744200-15-5P 744200-16-6P 744200-17-7P
 744200-18-8P 744200-19-9P 744200-20-2P
 744200-21-3P 744200-22-4P 744200-23-5P
 744200-24-6P 744200-25-7P 744200-26-8P
 744200-27-9P 744200-28-0P 744200-29-1P
 744200-30-4P 744200-31-5P 744200-32-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrazolo-fused benzodiazepine analogs as oxytocin agonists and vasopressin antagonists)


RN 500011-99-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● x HCl


RN 500012-01-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(phenylmethyl)-(9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 500012-02-2 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 500012-03-3 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[3-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-04-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-05-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-06-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 500012-07-7 CAPLUS



CN 1-Piperazinecarboxamide, 4-(2-aminoethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl



RN 500012-08-8 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[[4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-2-methylphenyl]methyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 500012-09-9 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 500012-10-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-11-3 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[2-chloro-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]hexahydro-4-methyl- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-12-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-butyl-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-13-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-methylbutyl)-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-15-7 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-16-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[3-(hydroxymethyl)phenyl]methyl]-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]-
(9CI) (CA INDEX NAME)



RN 500012-17-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[5-(hydroxymethyl)-2-furanyl]methyl]-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-19-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[4-[[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10/541,460




RN 500012-20-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-hydroxyethyl)-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




10/541,460


RN 500012-21-5 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]hexahydro-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-22-6 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]hexahydro-4-(2-methylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-23-7 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2,2-dimethylpropyl)hexahydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-25-9 CAPLUS

CN 1-Imidazolidinecarboxamide, 3-(cyclopropylmethyl)-N-[[4-[[4-(4,10-dihydro-1,10-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-26-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 500012-27-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,10-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[3-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-28-2 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]hexahydro-4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 500012-29-3 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 500012-30-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]hexahydro-1H-1,4-diazepin-1-yl]methyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 500012-31-7 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 500012-32-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-aminoethyl)-N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-


10/541,460

methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-33-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(3-aminopropyl)-N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-34-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 500012-35-1 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 500012-36-2 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[[[4,10-dihydro-1-(phenylmethyl)pyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 500012-37-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-38-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-methyl-
(9CI) (CA INDEX NAME)





RN 500012-39-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-ethyl-
(9CI) (CA INDEX NAME)





RN 500012-40-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-propyl-
(9CI) (CA INDEX NAME)





RN 500012-41-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-butyl-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 500012-42-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-pentyl-
(9CI) (CA INDEX NAME)





RN 500012-43-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-hexyl-
(9CI) (CA INDEX NAME)



RN 500012-44-2 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 500012-45-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-methylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-46-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-ethylbutyl)- (9CI) (CA INDEX NAME)





RN 500012-47-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[[4-(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)



RN 500012-49-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 500012-50-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-methyl-2-butenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-51-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-phenyl-(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 500012-52-2 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 500012-53-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[[2-(hydroxymethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 500012-54-4 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[4-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-55-5 CAPLUS
 CN Benzoic acid, 4-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon
 yl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-56-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[2-(1,2,3-thiadiazol-4-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 500012-57-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[3-(1,2,3-thiadiazol-4-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-58-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl) carbonyl]-2-methylphenyl]methyl]-4-[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-59-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 500012-60-2 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[[4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-2-methylphenyl]methyl]-4-[[5-(hydroxymethyl)-2-furanyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-61-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 500012-62-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[5-(hydroxymethyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-63-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-chloro-4-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]amino]carbonyl]-1-piperazinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 500012-64-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[4-chloro-5-(hydroxymethyl)-3-thienyl]methyl]-
N-[[4-[[4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-
yl]carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-65-7 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(1H-pyrrol-2-ylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-66-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(1-methyl-1H-pyrrol-2-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-67-9 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(1H-imidazol-2-ylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-68-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon-yl]-1-piperazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)





RN 500012-69-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[[4-(hydroxymethyl)-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)



RN 500012-70-4 CAPLUS


CN 3-Isoxazolecarboxylic acid, 5-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 500012-71-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-72-6 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon-yl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 500012-73-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[6-(hydroxymethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-74-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-oxopropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-75-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3-oxobutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-76-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(4-methylphenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-77-1 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon
yl]-, methyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 500012-78-2 CAPLUS
 CN 1-Piperazinepropanoic acid, 4-[[[[4-[[4-(10,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon
 yl]- (9CI) (CA INDEX NAME)




RN 500012-79-3 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[[[4-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-2-methylphenyl]methyl]piperazinebutanoic acid, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 500012-80-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-cyanoethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-81-7 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(2-azidoethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-82-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-[2-[(cyclopropylcarbonyl)amino]ethyl]-N-[[4-
 [(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-
 yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 500012-83-9 CAPLUS
 CN Cyclopropanecarboxylic acid, 2-[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



RN 500012-84-0 CAPLUS


CN 1-Piperazinecarboxamide, 4-[2-(acetyloxy)ethyl]-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 500012-85-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[2-(benzoyloxy)ethyl]-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-86-2 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 500012-87-3 CAPLUS
CN 1-Piperazineacetamide, N-cyclopropyl-4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 500012-88-4 CAPLUS


CN 1-Piperazineacetic acid, 4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 500012-89-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-, cyclopropylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-90-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-aminopropyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 500012-91-9 CAPLUS


CN 1-Piperazinecarboxamide, 4-[2-(diethylamino)ethyl]-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-92-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 500012-93-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 500012-94-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(4-hydroxybutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-95-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(4-hydroxy-2-butenyl)- (9CI) (CA INDEX NAME)



RN 500012-96-4 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(4-hydroxy-2-butyrynyl)- (9CI) (CA INDEX NAME)




RN 500012-97-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxybutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-98-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxy-3-phenylpropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-99-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(3-fluoro-2-hydroxypropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500013-00-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500013-01-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxy-3-methoxypropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500013-02-5 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-hydroxy-3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500013-03-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 500013-04-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 500013-05-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500013-06-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(2-ethoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)





RN 500013-07-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)





RN 500013-09-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-[(3-hydroxyphenyl)methyl]-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-yl)carbonyl]phenyl]methyl]- (9CI)
(CA INDEX NAME)





RN 500013-10-5 CAPLUS
 CN Benzoic acid, 4-[[4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-yl)carbonyl]phenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 500013-11-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-hydroxyethyl)-N-[[2-methyl-4-(4H-pyrazolo[5,1-c][1,4]benzodiazepin-5(10H)-ylcarbonyl)phenyl]methyl]- (9CI)
(CA INDEX NAME)



RN 500013-12-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 500013-13-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-oxopropyl)-(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500013-14-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-aminopropyl)-N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-(9CI) (CA INDEX NAME)





RN 500013-15-0 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-aminoethyl)-N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl]methyl]-(9CI) (CA INDEX NAME)





RN 500013-16-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-hydroxyethyl)-N-[[2-methyl-4-(pyrido[2,3-b][1,5]benzoxazepin-6(5H)-ylcarbonyl)phenyl)methyl]- (9CI) (CA INDEX NAME)





RN 500013-17-2 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)





RN 500013-18-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl]methyl]-4-(4-hydroxy-2-butenyl)- (9CI) (CA INDEX NAME)





RN 500013-19-4 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-4-(3-fluoro-2-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 744200-15-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-cyclopropylethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 744200-16-6 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[[4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-2-methylphenyl]methyl]-4-[[2-(hydroxymethyl)cyclopropyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-17-7 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(cyclopentylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-18-8 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(cyclobutylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-19-9 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-20-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclobutylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-21-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-22-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(cyclobutylmethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 744200-23-5 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 744200-24-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclobutylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-25-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-26-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclobutylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-27-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[3-chloro-4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-28-0 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[3-chloro-4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-4-(cyclobutylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-29-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclobutylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 744200-30-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(cyclobutylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]phenyl]methyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 744200-31-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[(2R)-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 744200-32-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-ethylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 500013-33-2P 500013-34-3P 500013-35-4P
500013-43-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of substituted pyrazolo-fused benzodiazepine analogs as
oxytocin agonists and vasopressin antagonists)


RN 500013-33-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-
thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]amino]carbonyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500013-34-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]amino]carbon
yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 500013-35-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-,


10/541,460

hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 500013-43-4 CAPLUS

CN Carbamic acid, [2-[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon
yl]-1-piperazinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:154435 CAPLUS

DOCUMENT NUMBER: 138:205088

TITLE: Preparation of substituted pyrazolo-fused
benzodiazepine analogs as oxytocin agonistsINVENTOR(S): Hudson, Peter Jeremy; Pitt, Gary Robert William;
Rooker, David Philip; Batt, Andrzej Roman; Laurent,
Celine Marguerite Simone; Roe, Michael Bryan

PATENT ASSIGNEE(S): Ferring BV, Neth.

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016316	A1	20030227	WO 2002-GB3593	20020806
WO 2003016316	A8	20031002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2453962	A1	20030227	CA 2002-2453962	20020806
EP 1421087	A1	20040526	EP 2002-747617	20020806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1543467	A	20041103	CN 2002-816006	20020806
NZ 530587	A	20041224	NZ 2002-530587	20020806
JP 2005501858	T	20050120	JP 2003-521238	20020806
ZA 2004000272	A	20041118	ZA 2004-272	20040114
IN 2004DN00211	A	20050401	IN 2004-DN211	20040129
NO 2004001819	A	20040514	NO 2004-1819	20040202
US 2005032777	A1	20050210	US 2004-486715	20040921
PRIORITY APPLN. INFO.:			GB 2001-20051	A 20010816
			WO 2002-GB3593	W 20020806
OTHER SOURCE(S):		MARPAT 138:205088		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [G1 = amino, fused polycyclic group; R1-3 = H, alkyl, alkoxy, F, Cl, Br; R4 = H, alk(en/yn)yl, Ph, etc.; X1 = O, NH; n = 1-2; m = 1-3] are prepared For instance, 4-cyano-3-methylbenzoic acid (preparation given) was coupled to 1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine (preparation given; PhMe, SOCl₂; CH₂Cl₂, Et₃N) and the product reduced to the corresponding aminomethyl derivative (MeOH, CoCl₂, NaBH₄), coupled to tert-Bu piperazine-1-carboxylate (DMF, i-Pr₂NEt, CDI),

deprotected (dioxane, 4N HCl) and reductively alkylated with cyclopropanecarboxaldehyde (THF, Et₃N, NaCNBH₃) to give II. I are selective and potent oxytocin agonists useful in the treatment of erectile dysfunction.

IT 500011-99-4P 500012-00-0P 500012-01-1P
 500012-02-2P 500012-03-3P 500012-04-4P
 500012-05-5P 500012-06-6P 500012-07-7P
 500012-08-8P 500012-09-9P 500012-10-2P
 500012-11-3P 500012-12-4P 500012-13-5P
 500012-14-6P 500012-15-7P 500012-16-8P
 500012-17-9P 500012-19-1P 500012-20-4P
 500012-21-5P 500012-22-6P 500012-23-7P
 500012-24-8P 500012-25-9P 500012-26-0P
 500012-27-1P 500012-28-2P 500012-29-3P
 500012-30-6P 500012-31-7P 500012-32-8P
 500012-33-9P 500012-34-0P 500012-35-1P
 500012-36-2P 500012-37-3P 500012-38-4P
 500012-39-5P 500012-40-8P 500012-41-9P
 500012-42-0P 500012-43-1P 500012-44-2P
 500012-45-3P 500012-46-4P 500012-47-5P
 500012-48-6P 500012-49-7P 500012-50-0P
 500012-51-1P 500012-52-2P 500012-53-3P
 500012-54-4P 500012-55-5P 500012-56-6P
 500012-57-7P 500012-58-8P 500012-59-9P
 500012-60-2P 500012-61-3P 500012-62-4P
 500012-63-5P 500012-64-6P 500012-65-7P
 500012-66-8P 500012-67-9P 500012-68-0P
 500012-69-1P 500012-70-4P 500012-71-5P
 500012-72-6P 500012-73-7P 500012-74-8P
 500012-75-9P 500012-76-0P 500012-77-1P
 500012-78-2P 500012-79-3P 500012-80-6P
 500012-81-7P 500012-82-8P 500012-83-9P
 500012-84-0P 500012-85-1P 500012-86-2P
 500012-87-3P 500012-88-4P 500012-89-5P
 500012-90-8P 500012-91-9P 500012-92-0P
 500012-93-1P 500012-94-2P 500012-95-3P
 500012-96-4P 500012-97-5P 500012-98-6P
 500012-99-7P 500013-00-3P 500013-01-4P
 500013-02-5P 500013-03-6P 500013-04-7P
 500013-05-8P 500013-06-9P 500013-07-0P
 500013-08-1P 500013-09-2P 500013-10-5P
 500013-11-6P 500013-12-7P 500013-13-8P
 500013-14-9P 500013-15-0P 500013-16-1P
 500013-17-2P 500013-18-3P 500013-19-4P
 500013-20-7P 500013-21-8P 500013-22-9P
 500013-23-0P 500013-24-1P 500013-25-2P
 500013-26-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrazolo-fused benzodiazepine analogs as oxytocin agonists)


RN 500011-99-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●_x HCl


RN 500012-00-0 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 500012-01-1 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-02-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 500012-03-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[3-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 500012-04-4 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 500012-05-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-06-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 500012-07-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-aminoethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 500012-08-8 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-09-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-10-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-11-3 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[2-chloro-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]hexahydro-4-methyl- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-12-4 CAPLUS

CN 1-Piperazinecarboxamide, 4-butyl-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-13-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-methylbutyl)-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-14-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-15-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 500012-16-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[3-(hydroxymethyl)phenyl]methyl]-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]-(9CI) (CA INDEX NAME)



RN 500012-17-9 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[[5-(hydroxymethyl)-2-furanyl]methyl]-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-19-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[4-[[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10/541,460




RN 500012-20-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-hydroxyethyl)-N-[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-21-5 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]hexahydro-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500012-22-6 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]hexahydro-4-(2-methylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 500012-23-7 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2,2-dimethylpropyl)hexahydro- (9CI) (CA INDEX NAME)




RN 500012-25-9 CAPLUS
 CN 1-Imidazolidinecarboxamide, 3-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1,10-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-26-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 500012-27-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1,10-dimethylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[3-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-28-2 CAPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]hexahydro-4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 500012-29-3 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 500012-30-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]hexahydro-1H-1,4-diazepin-1-yl]methyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 500012-31-7 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 500012-32-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-aminoethyl)-N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-


10/541,460

methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-33-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-aminopropyl)-N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 500012-34-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 500012-35-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,9-dihydro-1-methylpyrazolo[3,4-e]pyrido[3,2-b][1,4]diazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 500012-36-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[[4,10-dihydro-1-(phenylmethyl)pyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)





RN 500012-38-4 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-methyl-
 (9CI) (CA INDEX NAME)





RN 500012-39-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-ethyl-
(9CI) (CA INDEX NAME)





RN 500012-40-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-propyl-
(9CI) (CA INDEX NAME)




RN 500012-41-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-butyl-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 500012-42-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-pentyl-
(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-43-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-hexyl-
(9CI) (CA INDEX NAME)





RN 500012-44-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(3-methylbutyl)- (9CI) (CA INDEX NAME)





RN 500012-45-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-methylbutyl)- (9CI) (CA INDEX NAME)





RN 500012-46-4 CAPLUS



CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-ethylbutyl)- (9CI) (CA INDEX NAME)





RN 500012-47-5 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3,3-dimethylbutyl)- (9CI) (CA INDEX NAME)





RN 500012-49-7 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-propenyl)- (9CI) (CA INDEX NAME)





RN 500012-50-0 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-methyl-2-butenyl)- (9CI) (CA INDEX NAME)





RN 500012-51-1 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-phenyl-(9CI) (CA INDEX NAME)





RN 500012-52-2 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 500012-53-3 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[2-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-54-4 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[4-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-55-5 CAPLUS
 CN Benzoic acid, 4-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon
 yl]-1-piperazinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 500012-56-6 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[[2-(1,2,3-thiadiazol-4-yl)phenyl)methyl]- (9CI) (CA INDEX NAME)





RN 500012-57-7 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[3-(1,2,3-thiadiazol-4-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-58-8 CAPLUS



CN 1-Piperazinecarboxamide, N-[[4-[[4-(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-59-9 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-furanylmethyl)- (9CI) (CA INDEX NAME)





RN 500012-60-2 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[5-(hydroxymethyl)-2-furanyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-61-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, methyl ester
 (9CI) (CA INDEX NAME)





RN 500012-62-4 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[5-(hydroxymethyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-63-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-chloro-4-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, methyl ester
 (9CI) (CA INDEX NAME)





RN 500012-64-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[[4-chloro-5-(hydroxymethyl)-3-thienyl]methyl]-
 N-[[4-[[4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-
 yl]carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-65-7 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(1H-pyrrol-2-ylmethyl)- (9CI) (CA INDEX NAME)





RN 500012-66-8 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(1-methyl-1H-pyrrol-2-yl)methyl]- (9CI) (CA INDEX NAME)





RN 500012-67-9 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(1H-imidazol-2-ylmethyl)- (9CI) (CA INDEX NAME)





RN 500012-68-0 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon-yl]-1-piperazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)





RN 500012-69-1 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[[4-(hydroxymethyl)-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)





RN 500012-70-4 CAPLUS
 CN 3-Isoxazolecarboxylic acid, 5-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 500012-71-5 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 500012-72-6 CAPLUS
 CN 2-Pyridinecarboxylic acid, 6-[[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon-yl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 500012-73-7 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[[6-(hydroxymethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-74-8 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 500012-75-9 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(3-oxobutyl)- (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A





RN 500012-76-0 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(4-methylphenyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 500012-77-1 CAPLUS
 CN 1-Piperazinepropanoic acid, 4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon
 yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 500012-78-2 CAPLUS
 CN 1-Piperazinepropanoic acid, 4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon-yl]- (9CI) (CA INDEX NAME)




RN 500012-79-3 CAPLUS
 CN 1-Piperazinebutanoic acid, 4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon-yl]-, methyl ester (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A



RN 500012-80-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(2-cyanoethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 500012-81-7 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(2-azidoethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 500012-82-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-[2-[(cyclopropylcarbonyl)amino]ethyl]-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-83-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



RN 500012-84-0 CAPLUS


CN 1-Piperazinecarboxamide, 4-[2-(acetyloxy)ethyl]-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 500012-85-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[2-(benzoyloxy)ethyl]-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-86-2 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



RN 500012-87-3 CAPLUS


CN 1-Piperazineacetamide, N-cyclopropyl-4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 500012-88-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-2-methylphenyl]methyl]amino]carbon
yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500012-89-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[4-[[4-(2-methylphenyl)-5-oxo-1H-benzodiazepin-10-yl]methyl]amino]carbonyl]piperazine]acetic acid cyclopropylmethyl ester (9CI) (CA INDEX NAME)





RN 500012-90-8 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-aminopropyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 500012-91-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-[2-(diethylamino)ethyl]-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)





RN 500012-92-0 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[2-(4-morpholinyl)ethyl]-. (9CI) (CA INDEX NAME)





RN 500012-93-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 500012-94-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(4-hydroxybutyl)- (9CI) (CA INDEX NAME)





RN 500012-95-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-(4-hydroxy-2-butenyl)- (9CI) (CA INDEX NAME)



RN 500012-96-4 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(4-hydroxy-2-butyryl)- (9CI) (CA INDEX NAME)




RN 500012-97-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxybutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 500012-98-6 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxy-3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 500012-99-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[[4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-2-methylphenyl]methyl]-4-(3-fluoro-2-hydroxypropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500013-00-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500013-01-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxy-3-methoxypropyl)- (9CI) (CA INDEX NAME)





RN 500013-02-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[[4-(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-hydroxy-3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)





RN 500013-03-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)





RN 500013-04-7 CAPLUS

CN. 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)





RN 500013-05-8 CAPLUS



CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 500013-06-9 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[2-(2-ethoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)





RN 500013-07-0 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-4-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)





RN 500013-08-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[[4-(2-methylphenyl)-5-oxo-1H-pyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-2-methylphenyl]methyl]-4-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)





RN 500013-09-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-[(3-hydroxyphenyl)methyl]-N-[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-yl)carbonyl]phenyl)methyl]- (9CI)
(CA INDEX NAME)





RN 500013-10-5 CAPLUS

CN Benzoic acid, 4-[[4-[[[2-methyl-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-yl)carbonyl]phenyl]methyl]amino]carbonyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 500013-11-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(2-hydroxyethyl)-N-[[2-methyl-4-(4H-pyrazolo[5,1-c][1,4]benzodiazepin-5(10H)-ylcarbonyl)phenyl]methyl]- (9CI)
 (CA INDEX NAME)



RN 500013-12-7 CAPLUS


CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 500013-13-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-4-(2-oxopropyl)-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 500013-14-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-aminopropyl)-N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500013-15-0 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-aminoethyl)-N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-(9CI) (CA INDEX NAME)





RN 500013-16-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-(2-hydroxyethyl)-N-[[2-methyl-4-(pyrido[2,3-b][1,5]benzoxazepin-6(5H)-ylcarbonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 500013-17-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)





RN 500013-18-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl]methyl]-4-(4-hydroxy-2-butenyl)- (9CI) (CA INDEX NAME)





RN 500013-19-4 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(1,5-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)carbonyl]-2-methylphenyl)methyl]-4-(3-fluoro-2-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 500013-20-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-(cyclopropylmethyl)-, [2-methyl-4-[(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl ester (9CI)
(CA INDEX NAME)




RN 500013-21-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[[2-chloro-4-[(4,6,7,8-tetrahydro-5H-thieno[3,2-c]azepin-5-yl)carbonyl]phenyl]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 500013-22-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[[4-[(6,7-dihydro-5H-pyrrolo[1,2-a][1,5]benzodiazepin-5-yl)carbonyl]-2-methylphenyl]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 500013-23-0 CAPLUS
 CN 1,5-Diazocine-1(2H)-carboxylic acid, 5-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbonyl]hexahydro-, phenylmethyl ester (9CI)
 (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 500013-24-1 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[[4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl]carbonyl]-3-fluorophenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN. 500013-25-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-(cyclopropylmethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 500013-26-3 CAPLUS
 CN 1-Piperazinecarboxamide, 4-(2-aminoethyl)-N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 500013-33-2P 500013-34-3P 500013-35-4P
500013-43-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of substituted pyrazolo-fused benzodiazepine analogs as
oxytocin agonists)


RN 500013-33-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-methyl-4-[(5,6,7,8-tetrahydro-4H-
thieno[3,2-b]azepin-4-yl)carbonyl]phenyl]methyl]amino]carbonyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 500013-34-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon
yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 500013-35-4 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 500013-43-4 CAPLUS
 CN Carbamic acid, [2-[4-[[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]amino]carbon-yl]-1-piperazinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:102855 CAPLUS

DOCUMENT NUMBER: 128:167443

TITLE: Novel compounds [cyclooctylene
bis(piperazinecarboxylates) and analogs] and
compositions for treating diseases associated with
tryptase activityINVENTOR(S): Dener, Jeffrey Mark; Kuo, Elaine Yee-Lin; Rice, Ken
Duane; Wang, Vivian Rueywen; Young, Wendy Beth

PATENT ASSIGNEE(S): Arris Pharmaceutical Corporation, USA

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804537	A1	19980205	WO 1997-US13422	19970730
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2262542	A1	19980205	CA 1997-2262542	19970730
AU 9739670	A	19980220	AU 1997-39670	19970730
AU 733621	B2	20010517		
EP 934293	A1	19990811	EP 1997-937066	19970730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1226892	A	19990825	CN 1997-196877	19970730
CN 1073103	B	20011017		
NZ 333713	A	20001222	NZ 1997-333713	19970730
HU 200003267	A2	20010628	HU 2000-3267	19970730
HU 200003267	A3	20020228		
JP 2001509787	T	20010724	JP 1998-509136	19970730
FI 9900171	A	19990323	FI 1999-171	19990129
NO 9900433	A	19990325	NO 1999-433	19990129
KR 2000029679	A	20000525	KR 1999-700757	19990129
LV 12291	B	20000420	LV 1999-27	19990218
LT 4587	B	19991227	LT 1999-19	19990301
LV 12458	B	20000920	LV 2000-30	20000225
LV 12459	B	20000920	LV 2000-31	20000225
PRIORITY APPLN. INFO.:			US 1996-23139P	P 19960730
			US 1997-895772	A 19970717
			WO 1997-US13422	W 19970730
			LV 1999-990027	A3 19990218

OTHER SOURCE(S): MARPAT 128:167443

GI



II

AB The invention relates to novel compds. (R1X1X2X3X4)-X5-(X6X7X8X9R2) (I), which are tryptase inhibitors, and their pharmaceutically acceptable salts and N-oxides, as well as their uses as therapeutic agents, and methods of their preparation [wherein X5 = (hetero)cycloalkylene, (hetero)arylene; X4, X6 = bond, alkylene; X1, X9 = bond, CO, CO2, OCO, CONR3, NR3CO, etc.; R3 = H, alkyl, cycloalkyl; X3, X7 = CO, CO2, OCO, CONR3, NR3CO, etc.; X2, X8 = (hetero)alkylene and/or cycloalkylene; R1 = amino, amidino, guanidino, certain N-heterocycles, etc., with optional (hetero)alkylene or other bridge; R2 = amino, 1-iminoethyl, methylamino, or certain N-heterocycles, with required or optional alkylene or other bridge]. The compds. are useful for treating a variety of conditions, including asthma, rheumatoid arthritis, and conjunctivitis. For instance, tert-Bu 4-[(4-guanidinobenzyl)carbamoyl]-1-piperazinecarboxylate trifluoroacetate underwent deprotection with CF3CO2H and amidation with cis-1,5-cyclooctylene chloroformate 4-(tert-butoxycarbonyl)-1-piperazinecarboxylate (77%), followed by a second deprotection and reaction with tert-Bu 4-(2-isocyanatoethyl)-1-piperidinecarboxylate, to give title compound II. Compds. I inhibited human tryptase in vitro with IC50 in the range of 0.0001 to 41 μ M.

IT 202978-07-2P 202978-08-3P 202978-09-4P
202978-10-7P 202978-11-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclooctylene bis(piperazinecarboxylates) and analogs as tryptase inhibitors)


RN 202978-07-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[4-[(aminoiminomethyl)amino]phenyl]methyl]amino]carbonyl]-, [4-[[4-[[[2-(4-piperidinyl)ethyl]amino]carbonyl]-1-piperazinyl]carbonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 202978-08-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[4-[(aminoiminomethyl)amino]phenyl]methyl]amino]carbonyl-, [4-[[4-[[[3-(4-piperidinyl)propyl]amino]carbonyl]-1-piperazinyl]carbonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 202978-09-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[4-[(aminoiminomethyl)amino]phenyl]methyl]amino]carbonyl-, [4-[[4-[[[4-(4-piperidinyl)butyl]amino]carbonyl]-1-piperazinyl]carbonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 202978-10-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[2-(4-piperidinyl)ethyl]amino]carbonyl]-, [4-[[4-[[[4-[(aminoiminomethyl)amino]phenyl]methyl]amino]carbonyl]-1-piperazinyl]carbonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 202978-11-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[3-(4-piperidinyl)propyl]amino]carbonyl]-, [4-[[4-[[[4-[(aminoiminomethyl)amino]phenyl]methyl]amino]carbonyl]-1-piperazinyl]carbonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/541,460

=>